Skip to main content

SCYNEXIS, Inc. (SCYX)

NASDAQ: SCYX · IEX Real-Time Price · USD
6.38
-0.29 (-4.35%)
At close: Dec 3, 2021 4:00 PM
6.42
0.04 (0.63%)
After-hours:Dec 3, 2021 7:44 PM EST
Market Cap152.80M
Revenue (ttm)12.57M
Net Income (ttm)-46.33M
Shares Out23.95M
EPS (ttm)-2.60
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume503,478
Open6.60
Previous Close6.67
Day's Range6.00 - 6.64
52-Week Range4.90 - 10.25
Beta2.12
AnalystsStrong Buy
Price Target23.50 (+268.3%)
Earnings DateNov 10, 2021

About SCYX

SCYNEXIS, Inc., a biotechnology company, delivers therapies for the treatment fungal infections in the United States. It is developing its lead product candidate, ibrexafungerp, as a novel oral and intravenous drug for the treatment of various fungal infections, including vulvovaginal candidiasis, invasive aspergillosis, invasive candidiasis, and refractory invasive fungal infections. The company develops ibrexafungerp, which has completed Phase II clinical trials for the treatment of vulvovaginal candidiasis. It has research collaborations wit...

IndustryPharmaceuticals
IPO DateMay 2, 2014
Employees38
Stock ExchangeNASDAQ
Ticker SymbolSCYX
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 7 analysts, the average rating for SCYNEXIS stock is "Strong Buy." The 12-month stock price forecast is 23.50, which is an increase of 268.34% from the latest price.

Price Target
$23.50
(268.34% upside)
Analyst Consensus: Strong Buy

News

SCYNEXIS Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

JERSEY CITY, N.J., Dec. 03, 2021 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant ...

18 hours ago - GlobeNewsWire

SCYNEXIS Reports the Exercise of Warrants Totalling $7.9 Million

JERSEY CITY, N.J., Dec. 03, 2021 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant ...

1 day ago - GlobeNewsWire

BREXAFEMME® (Ibrexafungerp Tablets) Receives 2021 Popular Science Best of What's New Award in the Health Category

JERSEY CITY, N.J., Dec. 01, 2021 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant ...

3 days ago - GlobeNewsWire

SCYNEXIS to Host Ibrexafungerp Hospital Pipeline Update Call and KOL Webcast for Investors on December 6

JERSEY CITY, N.J., Nov. 29, 2021 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant ...

5 days ago - GlobeNewsWire

Scynexis (SCYX) Reports Q3 Loss, Tops Revenue Estimates

Scynexis (SCYX) delivered earnings and revenue surprises of 92.41% and 3.20%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

3 weeks ago - Zacks Investment Research

SCYNEXIS Reports Third Quarter 2021 Financial Results and Provides Corporate Update

JERSEY CITY, N.J., Nov. 10, 2021 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant ...

3 weeks ago - GlobeNewsWire

SCYNEXIS Announces Successful Completion of Phase 1 Trial Evaluating Intravenous (IV) Formulation of Ibrexafungerp

Safety and tolerability of new liposomal IV formulation confirmed to reach target exposure in single ascending dose (SAD) and multiple ascending dose (MAD) study Safety and tolerability of new liposomal...

3 weeks ago - GlobeNewsWire

SCYNEXIS to Provide a Corporate Update and Report Third Quarter 2021 Financial Results on November 10

JERSEY CITY, N.J., Nov. 03, 2021 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant ...

1 month ago - GlobeNewsWire

SCYNEXIS Pivotal Phase 3 VANISH-303 Trial Results Published in Clinical Infectious Diseases Demonstrate Significant S...

JERSEY CITY, N.J., Oct. 21, 2021 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant ...

1 month ago - GlobeNewsWire

SCYNEXIS to Present Pooled Data Analysis Results Demonstrating Consistent Efficacy and Safety Outcomes Across Two Pha...

JERSEY CITY, N.J., Oct. 13, 2021 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant ...

1 month ago - GlobeNewsWire

SCYNEXIS Announces Preclinical Data at the 10th Trends in Medical Mycology Meeting Supporting Potential of Ibrexafung...

JERSEY CITY, N.J., Oct. 11, 2021 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant ...

1 month ago - GlobeNewsWire

Antimicrobials Working Group Highlights Member Company Participation at IDWeek 2021

WASHINGTON, Sept. 30, 2021 /PRNewswire/ -- The Antimicrobials Working Group (AWG), a coalition of companies with the mission to combat drug resistant infections and spur life-saving innovations, today a...

2 months ago - PRNewsWire

SCYNEXIS Presents Interim Analysis from FURI at Virtual IDWeek 2021 Showing Favorable Therapeutic Response in Severe ...

Subpopulation analysis of 74 patients from ongoing Phase 3 FURI study demonstrated similar efficacy against multiple serious fungal infections Subpopulation analysis of 74 patients from ongoing Phase 3 ...

2 months ago - GlobeNewsWire

SCYNEXIS to Present Data on Oral Ibrexafungerp at IDWeek 2021 from Interim Analyses of Phase 3 FURI Clinical Trial Sh...

Analysis of subpopulations from a total of 74 patients evaluated to date from FURI includes outcomes by disease, bone and joint infections, and mouth and throat candidiasis Analysis of subpopulations fr...

2 months ago - GlobeNewsWire

SCYNEXIS Announces U.S. Availability of BREXAFEMME® (ibrexafungerp tablets), the First New Antifungal Class of Therap...

JERSEY CITY, N.J., Sept. 22, 2021 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant...

2 months ago - GlobeNewsWire

SCYNEXIS Announces Hansoh Pharma's Application to National Medical Products Administration (NMPA) in China for Phase ...

Submission is part of the Hansoh Pharma licensing agreement and strategic partnership to research, develop and commercialize ibrexafungerp in the Greater China region Submission is part of the Hansoh Ph...

2 months ago - GlobeNewsWire

SCYNEXIS Reports Second Quarter 2021 Financial Results and Provides Corporate Update

JERSEY CITY, N.J., Aug. 16, 2021 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant ...

3 months ago - GlobeNewsWire

SCYNEXIS Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

JERSEY CITY, N.J., Aug. 02, 2021 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant ...

4 months ago - GlobeNewsWire

SCYNEXIS to Present Commercial Launch Update for BREXAFEMME® (ibrexafungerp tablets)

JERSEY CITY, N.J., June 23, 2021 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant ...

5 months ago - GlobeNewsWire

SCYNEXIS to Present at the BIO Digital International Convention 2021

JERSEY CITY, N.J., June 11, 2021 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant ...

5 months ago - GlobeNewsWire

SCYNEXIS Confirms that BREXAFEMME® (ibrexafungerp tablets) Qualifies for 10 Years of Regulatory Exclusivity for Vagin...

JERSEY CITY, N.J., June 09, 2021 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant ...

5 months ago - GlobeNewsWire

Scynexis Scores FDA Nod For Brexafemme, Oral Treatment For Vaginal Yeast Infection

The FDA has approved Scynexis Inc's (NASDAQ: SCYX) Brexafemme (ibrexafungerp tablets) for oral use in patients with vulvovaginal candidiasis (VVC), also known as a vaginal yeast infection. Brexafemme re...

6 months ago - Benzinga

SCYNEXIS Announces FDA Approval of BREXAFEMME® (ibrexafungerp tablets) as the First and Only Oral Non-Azole Treatment...

JERSEY CITY, N.J., June 02, 2021 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant ...

6 months ago - GlobeNewsWire

SCYNEXIS Reports First Quarter 2021 Financial Results and Provides Corporate Update

JERSEY CITY, N.J., May 17, 2021 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant i...

6 months ago - GlobeNewsWire

Scynexis Raises $60M Via Term Loan Ahead Of Expected Approval Of Vaginal Yeast Infection Treatment

Scynexis Inc (NASDAQ: SCYX) is taking out a loan to ensure it can hit the ground running for a potential commercial launch of ibrexafungerp for vaginal yeast infections as the PDUFA date of June 1 is ju...

6 months ago - Benzinga